Pacific Biosciences Of California (PACB) Free Cash Flow Growth (1y) (2011 - 2026)
Pacific Biosciences Of California (PACB) Free Cash Flow Growth (1y) (2011 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 154.42 Bn | 147.76 Bn | 6.27 Bn | -1.82% |
| 2 | Stryker | 118.12 Bn | 115.25 Bn | 3.81 Bn | 226.77% |
| 3 | Medtronic | 101.72 Bn | 93.55 Bn | 5.76 Bn | 9.73% |
| 4 | Boston Scientific | 67.19 Bn | 65.98 Bn | 3.61 Bn | -51.69% |
| 5 | Edwards Lifesciences | 50.69 Bn | 47.02 Bn | 1.29 Bn | -109.40% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | 133.09% |
| 7 | Dexcom | 28.09 Bn | 26.97 Bn | 750.30 Mn | 363.84% |
| 8 | GE HealthCare Technologies | 28.08 Bn | 26.02 Bn | 1.98 Bn | 108.16% |
| 9 | Steris | 19.80 Bn | 19.37 Bn | 697.10 Mn | 29.12% |
| 10 | Pacific Biosciences Of California | 426.62 Mn | 150.66 Mn | 12.84 Mn | -5.04% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.04% |
| Dec 31, 2025 | 38.23% |
| Sep 30, 2025 | 58.32% |
| Jun 30, 2025 | 46.31% |
| Mar 31, 2025 | 42.88% |
| Dec 31, 2024 | 45.85% |
| Sep 30, 2024 | 32.32% |
| Jun 30, 2024 | -26.66% |
| Mar 31, 2024 | 19.16% |
| Dec 31, 2023 | 8.99% |
| Sep 30, 2023 | 1.83% |
| Jun 30, 2023 | 31.86% |
| Mar 31, 2023 | -19.05% |
| Dec 31, 2022 | -89.49% |
| Jun 30, 2022 | -273.72% |
| Mar 31, 2022 | -251.70% |
| Dec 31, 2021 | -141.10% |
| Jun 30, 2021 | 28.32% |
| Mar 31, 2021 | -131.24% |
| Dec 31, 2020 | 21.78% |